Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.

Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, Young G, Bidlingmaier C, Brandao LR, Ettingshausen CE, Gringeri A, Kenet G, Knöfler R, Kreuz W, Kurnik K, Manner D, Santagostino E, Mannucci PM, Nowak-Göttl U.

J Thromb Haemost. 2010 Jun;8(6):1256-65. doi: 10.1111/j.1538-7836.2010.03823.x. Epub 2010 Mar 17. Review.

2.

Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.

Mancuso ME, Mannucci PM, Rocino A, Garagiola I, Tagliaferri A, Santagostino E.

J Thromb Haemost. 2012 May;10(5):781-90. doi: 10.1111/j.1538-7836.2012.04691.x.

3.

Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.

Qadura M, Waters B, Burnett E, Chegeni R, Bradshaw S, Hough C, Othman M, Lillicrap D.

Blood. 2009 Jul 23;114(4):871-80. doi: 10.1182/blood-2008-09-174649. Epub 2009 May 1.

4.

Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.

Lusher JM.

Haematologica. 2000 Oct;85(10 Suppl):2-5; discussion 5-6. Review.

PMID:
11187864
5.

Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.

Musso R.

Drugs Today (Barc). 2008 Oct;44(10):735-50. doi: 10.1358/dot.2008.44.10.1284765. Review.

PMID:
19137127
6.

Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.

Ettingshausen CE, Kreuz W.

Haemophilia. 2006 Dec;12 Suppl 6:102-6. Review.

PMID:
17123402
7.

Superior in vivo response of recombinant factor VIII concentrate in children with hemophilia A.

Kelly KM, Butler RB, Farace L, Cohen AR, Manno CS.

J Pediatr. 1997 Apr;130(4):537-40.

PMID:
9108849
8.
9.

Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.

Fukui H, Yoshioka A, Shima M, Tanaka I, Koshihara K, Fukutake K, Fujimaki M.

Int J Hematol. 1991 Oct;54(5):419-27.

PMID:
1756252
10.

Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review.

Franchini M, Tagliaferri A, Mengoli C, Cruciani M.

Crit Rev Oncol Hematol. 2012 Jan;81(1):82-93. doi: 10.1016/j.critrevonc.2011.01.002. Epub 2011 Jan 31. Review.

PMID:
21277222
11.

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, Borel-Derlon A, Claeyssens S, Laurian Y, Calvez T; FVIII-LFB and Recombinant FVIII study groups.

Blood. 2006 Jan 1;107(1):46-51. Epub 2005 Sep 15.

12.

Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.

Gringeri A, Monzini M, Tagariello G, Scaraggi FA, Mannucci PM; Emoclot15 Study Members.

Haemophilia. 2006 Mar;12(2):128-32.

PMID:
16476086
13.

Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. Kogenate Japanese Clinical Study Group.

Shima M, Sawamoto Y, Nakai H, Kamisue S, Murakami T, Morichika S, Tanaka I, Hayashi K, Yoshioka A.

Int J Hematol. 1995 Jul;62(1):35-43.

PMID:
7670006
14.

Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies.

Aledort LM, Navickis RJ, Wilkes MM.

J Thromb Haemost. 2011 Nov;9(11):2180-92. doi: 10.1111/j.1538-7836.2011.04472.x.

15.

The uptake of recombinant Factor VIII in the Netherlands.

Zwart-van Rijkom JE, Plug I, Rosendaal FR, Leufkens HG, Broekmans AW; Study Group Haemophilia in The Netherlands.

Br J Haematol. 2002 Nov;119(2):332-41.

PMID:
12406065
16.

Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation.

Lusher J, Abildgaard C, Arkin S, Mannucci PM, Zimmermann R, Schwartz L, Hurst D.

J Thromb Haemost. 2004 Apr;2(4):574-83.

17.

Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.

Strauss T, Lubetsky A, Ravid B, Bashari D, Luboshitz J, Lalezari S, Misgav M, Martinowitz U, Kenet G.

Haemophilia. 2011 Jul;17(4):625-9. doi: 10.1111/j.1365-2516.2010.02464.x. Epub 2011 Feb 7.

PMID:
21299743
18.

Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII.

Montalvão SA, Tucunduva AC, Siqueira LH, Sambo AL, Medina SS, Ozelo MC.

Haemophilia. 2015 Jul;21(4):e281-5. doi: 10.1111/hae.12647. Epub 2015 Apr 30.

PMID:
25929310
19.

Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A.

Yoshioka A, Fukutake K, Takamatsu J, Shirahata A; Kogenate Post-Marketing Surveillance Study Group.

Int J Hematol. 2003 Dec;78(5):467-74. Erratum in: Int J Hematol. 2004 Feb;79(2):205.

PMID:
14704043
20.

Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.

Kreuz W, Ettingshausen CE, Zyschka A, Oldenburg J, Saguer IM, Ehrenforth S, Klingebiel T.

Semin Thromb Hemost. 2002 Jun;28(3):285-90.

PMID:
12098090
Items per page

Supplemental Content

Write to the Help Desk